Screening Libraries
| Cat. | Size | Price | Stock | |
| L20097 | 1mg/well * 2 Compounds | Inquiry | In stock | Contact Us |
| L20097 | 100uL/well (10mM solution) * 2 Compounds | Inquiry | In stock |
| manager@chemfaces.com | |
| Tel | (0086)-27-8423-7683 |
| Shelf Life | (0086)-27-84254680 |
| Manufacturer | Wuhan ChemFaces Biochemical Co., Ltd. |
| Container | 96 Well Format Sample |
| Storage | Protected from air and light, refrigerate or freeze(2-8 °) |
| Shelf Life | 24 months (2-8 °) |
| Intended Use | For research use only. Not for human use. Not sell to patients |
| 1. The products in the ChemFaces screening libraries are all from plants. |
| 2. The biological activities or pharmacological activities of all the ChemFaces products are derived from the databases of all over the world the latest literatures, you can according to the product manuals on our website to access the relevant literatures, hope that our informations can give some inspirations and help to your research. |
| 3.The collections of unique natural products, which include antioxidants, anti-inflammatory, antibacterial, anticancer, and ect. Can be used for high throughput screening (HTS) and high content screening (HCS), is to help you carry out new drug screening, the emergence of new indications and other professional tools. |
| 4.Structurally diverse, medicinally active, and cell permeable, NMR and HPLC validated to ensure high purity. |
| 5. ChemFaces offers customized bioactive screening libraries , whereby you choose the specific compounds you want in the library, the quantities, plate map, concentration, and format (dry/solid or DMSO solution). |
| Catalog No. | Information |
| CFN90002 | Silodosin Silodosin, a selective α-1a receptor antagonist, can increase passage of distal ureteral stones. Silodosin can temporarily improve lower urinary tract symptoms (LUTS), but do not improve the bladder outlet obstruction index (BOOI) after implantation in the prostate, it is a useful option for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia .Silodosin appears to suppress ejaculation in a relatively higher percent of trial participants, this suppression of ejaculation by silodosin suggested its potential for treating premature ejaculation. |
| CFN92008 | Eurycomanone Eurycomanone has anti-cancer activity, it is cytotoxic on HepG2 cells by inducing apoptosis through the up-regulation of p53 and Bax, and down-regulation of Bcl-2. |
